# Halozyme Therapeutics, Inc. (HALO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/HALO
## Company Profile
- Ticker: HALO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 110.19 USD
- Market cap: 7861669640 USD
- Last updated: 2026-09-04
## Business Overview
Halozyme Therapeutics is a biopharmaceutical company best known for its enzyme technology platform that enables subcutaneous drug delivery. The business combines licensed technology revenue with development activity around oncology and other therapeutic areas.
## Why The Stock Is Moving

As of Sep 4, 2026, HALO closed down 0.51% at $110.19. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Halozyme is a U.S.-based specialty biotech company. It sits in platform-enabled drug delivery and oncology-adjacent therapeutics.

## Business Model

The company generates value through royalty income, partner relationships, and technology licensing tied to subcutaneous formulation. Investors follow licensing growth, partner adoption, and whether the technology platform continues to expand across the industry.

## Landscape Position

Halozyme occupies a unique position in biotech because it monetizes platform technology rather than relying only on its own clinical pipeline. That makes it less binary than many development-stage peers, but still catalyst-sensitive around deal flow and partner uptake.

## Future Catalysts

- Halozyme's catalysts are partner launches on the ENHANZE platform, especially Darzalex Faspro and VYVGART Hytrulo royalty growth, plus any new subcutaneous-drug-delivery deal. The stock moves when royalty durability and partner breadth both keep expanding.

## Recent News
- 2009-01-26 13:00 EST — [Halozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20](https://biopharmsignal.com/news/HALO/halozyme-therapeutics-presents-positive-pre-clinical-single-agent-data-for-pegph-3d6f191c) — Source: Halozyme Therapeutics, Inc.
- 2009-01-15 13:00 EST — [Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial With Second Biologic](https://biopharmsignal.com/news/HALO/halozyme-therapeutics-announces-roche-begins-phase-1-clinical-trial-with-second--0c57240c) — Source: Halozyme Therapeutics, Inc.
- 2009-01-08 13:00 EST — [Halozyme to Present At J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/HALO/halozyme-to-present-at-j-p-morgan-healthcare-conference-a8eb1003) — Source: Halozyme Therapeutics, Inc.